News Briefs

Incyte has received the Food and Drug Administration’s clearance for Pemazyre (pemigatinib), a selective fibroblast growth factor receptor inhibitor.

The medication is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

“The approval of Pemazyre represents an important treatment advancement for people living with MLNs with FGFR1 rearrangement who currently have limited treatment options,” said Hervé Hoppenot, CEO of Incyte. “These are complex hematologic malignancies with a range of presentations, and this approval highlights Incyte’s continued leadership and commitment to advancing care for patients with rare blood cancers.”

MLNs with FGFR1 rearrangement are extremely rare and aggressive blood cancers that may impact less than 1 in 100,000 people in the United States, the company noted.

“In patients with relapsed or refractory MLNs with FGFR1 rearrangement treated with Pemazyre in FIGHT-203, the high rate of complete response and complete cytogenetic response in patients with chronic phase disease and the high rate of complete cytogenetic response in patients with blast phase disease is clinically meaningful, especially in light of the lack of these specific responses with existing first-line treatments,” said Srdan Verstovsek, professor, department of Leukemia, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center and principal investigator for the FIGHT-203 study.

Pemazyre, a fibroblast growth factor receptor inhibitor, is the first targeted treatment approved for use in the United States for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Pemazyre also is indicated for the treatment of adults with relapsed or refractory previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on the overall response rate and duration of response. Continued approval may be contingent on verification and description of clinical benefit in a confirmatory trial(s).

One Brand is adding a bit of a crunch to its popular protein bars with a new product line — One Crunch.

Featuring 12 g of protein and 1 g of sugar, the bars come in peanut butter chocolate chip, cinnamon French toast and marshmallow treat varieties.

“After a day of working hard, new One Crunch protein bars are the perfect way to power through afternoon hunger and fatigue,” said Eric Clawson, One Brands’ general manager. “One Brands is known for our flavor innovation, and you can expect more exciting and delicious flavors like marshmallow or French toast, delivered without all the sugar and combined with powerful protein in this new line of bars.”

One Crunch bars are available for purchase online and in select stores at Walmart. The products will be launched at a later date on Amazon and Target.

A new popcorn is joining the General Mills family.

Trix Popcorn is the latest launch from the company, which is a crunchy popcorn snack that contains a Trix-flavored fruity glaze along with bits of the cereal, the company said.

Inspired by other cereal and popcorn snack flavors that have been released, including Cinnamon Toast Crunch popcorn with Cinnadust Glaze and Cocoa Puffs popcorn with Cocoa Glaze, the snack features a balance of sweet and salty notes.

Consumers currently can find Trix Popcorn available at Sam’s Club in a 20-oz. bag that retails for $6.48 and in a 7-oz. bag that will retail for $3.69 at Walmart beginning in October.

Glamnetic is showcasing a brand new press-on manicure collection designed for those who prefer a short round nail shape.

The Choose Your Vibe line features eight designs that include Lots of Love, Pretty Picnic, A Good Day, Shroomies, Pure Intentions, Day Trip, Mu Cherie and Hot Dot.

Like all of Glamnetic’s press on, each set in this new collection is reusable, customizable and made with high-quality material that is easy to file or clip and will not bend or split, the company said.

Made to last up to three weeks of wear, the nails are vegan, cruelty-free and topped with a layer of UV coating to achieve a salon-quality finish.

Each nail design retails for $14.99 each and the entire collection is available for $89.94 online.

Sally Hansen is teaming up with Netflix to launch a collection of polishes that will have consumers feeling as if they are in a fantasy novel.

Inspired by the “School for Good & Evil,” premiering on the streaming platform, the Sally Hansen Miracle Gel X Netflix The School for Good & Evil collection was influenced by the young adult novel turned film.

Designed to help consumers achieve a perfect manicure with imaginative shades, Sally Hansen’s Miracle Gel line features color set technology, lasts up to eight days and does not require a UV lamp for application.

Available shades include True Beauty Comes from Within; The Storian; Not What It Gleams; Lovey Dovey; Good is Great; Can’t Settle, Won’t Settle; Fresh Villainy; It’s Better Being Bad; Magic Mirror and Lesso Go.

The Sally Hansen Miracle Gel X Netflix The School for Good & Evil collection will be available in September at mass market, drug store, food and ecommerce retailers nationwide.

Haleon is previewing a new product, which is among the first consumer health product releases since the company’s launch.

Just in time for cold and flu season, this September consumers will be able to pick up Theraflu Flu Relief Max Strength.

Featuring 1,000 mg of acetaminophen, the product offers relief for several common flu symptoms — including fever, body ache, sore throat pain, cough and runny nose — for up to 6 hours and is available in a variety of formulations for all types of lifestyles and preferences, the company said.

Theraflu Flu Relief Max Strength will be available over the counter in September and online in mid-late September.